Clinical Trial Recruitment Agents: Claude Opus 4.7 in Pharma

Table of Contents

1. Why Clinical Trial Recruitment Fails—And How Agents Fix It
2. Agentic AI in Pharma: The Core Pattern
3. Reading EMR Cohorts at Scale
4. Eligibility Screening with Claude Opus 4.7
5. Patient Preference Mapping and Consent
6. Human Review Gates for AU HRECs
7. Building the Recruitment Agent: Architecture and Implementation
8. Real-World Results and ROI
9. Compliance, Risk, and Governance
10. Getting Started: Your First 90 Days

---

Why Clinical Trial Recruitment Fails—And How Agents Fix It

Clinical trial recruitment is broken. Across the pharmaceutical industry, 80% of trials miss enrolment targets. Patient acquisition costs balloon to $1,500–$5,000 per recruited participant. Sites spend weeks manually screening electronic medical records (EMRs), cross-referencing eligibility criteria, and chasing down consent. Regulators demand audit trails. Human resources are stretched. Time-to-market slips.

The root cause isn’t complexity—it’s volume and repetition. A single trial might have 50+ inclusion/exclusion criteria. A hospital system holds records for 100,000+ patients. Manually reviewing that cohort takes months. Worse, human reviewers introduce inconsistency: one screener might interpret “hypertension” differently from another, leading to protocol deviations and regulatory pushback.

Agentic AI—specifically large language models like Claude Opus 4.7—changes the equation. These models can read unstructured EMR data, apply nuanced eligibility logic, flag patient preferences, and hand off to human reviewers with full context and audit trails. The result: faster recruitment, lower costs, better compliance, and fewer protocol violations.

This guide walks you through the architecture, patterns, and governance required to deploy clinical trial recruitment agents in Australian healthcare settings, where HREC (Human Research Ethics Committee) requirements add a layer of human-in-the-loop oversight that actually strengthens the system.

---

Agentic AI in Pharma: The Core Pattern

Before diving into implementation, you need to understand what “agentic” means in this context—and why it matters for trial recruitment.

Traditional automation in pharma is rule-based: if-then logic, rigid workflows, database queries. If a patient’s age is between 18 and 65, and creatinine is below X, and no prior cancer diagnosis, then flag them. This approach works for clean, structured data. But EMRs are messy. Clinical notes are free text. Lab values are scattered across legacy systems. Dates are inconsistent. And eligibility criteria often require judgment calls—“stable disease,” “adequate renal function,” “no significant comorbidities”—that rules can’t capture.

Agentic AI flips the model. Instead of pre-coding every rule, you give Claude Opus 4.7 the trial protocol, the eligibility criteria, and the patient’s EMR. The model reads the protocol, understands the intent behind each criterion, then applies that understanding to the patient’s messy, real-world data. It explains its reasoning. It flags uncertainties. It asks clarifying questions. It learns from human feedback.

This is fundamentally different from chatbots or traditional NLP. The agent is autonomous—it can plan multi-step workflows, retrieve data from multiple sources, reason about edge cases, and hand off to humans at the right moment. It’s not just answering questions; it’s executing a complex process.

For trial recruitment, the agentic pattern looks like this:

1. Intake: Load the trial protocol and eligibility criteria into the agent’s context.
2. Cohort discovery: Query the hospital’s EMR system to identify candidate patients (e.g., all patients with a diagnosis of Type 2 diabetes in the past 12 months).
3. EMR reading: For each candidate, the agent reads their full medical record—structured data (labs, vitals, medications) and unstructured data (clinical notes, discharge summaries).
4. Eligibility assessment: The agent applies the trial’s inclusion/exclusion criteria, flagging matches, near-misses, and uncertainties.
5. Preference mapping: The agent identifies patient preferences (e.g., “prefers daytime appointments,” “has childcare constraints”) from the EMR and care team notes.
6. Human review: The agent hands off to a clinical coordinator with a structured summary, reasoning, and confidence scores.
7. Consent and enrolment: Once approved, the agent tracks consent status, appointment scheduling, and follow-up.

This pattern is not hypothetical. Advancing Claude in Healthcare and the Life Sciences documents real-world applications of Claude in clinical workflows, including protocol drafting and patient screening. The key is that Claude Opus 4.7 has been trained on medical literature, clinical guidelines, and regulatory documents, giving it domain knowledge that earlier models lacked.

Compare this to agentic AI vs traditional automation, where rule-based systems break down in the face of unstructured data and require constant maintenance. Agentic systems adapt.

---

Reading EMR Cohorts at Scale

The first bottleneck in trial recruitment is finding eligible patients. Traditional approach: a clinical coordinator manually searches the EMR using diagnosis codes, lab values, and medication lists. For a cohort of 10,000 patients, this takes weeks.

An agentic system accelerates this by orders of magnitude.

Structured Query Layer

Start with what you can automate cleanly. Most EMR systems (Epic, Cerner, Medidata) expose APIs or export tools. Use these to pull structured data:

• Diagnosis codes: ICD-10 codes for inclusion diagnoses (e.g., E11 for Type 2 diabetes).
• Lab values: Creatinine, HbA1c, liver function tests, lipid panels from the past 12 months.
• Medications: Current and recent prescriptions, with dates.
• Demographics: Age, sex, language, postal code (for site proximity).
• Vitals: Blood pressure, BMI, recent measurements.
• Appointment history: Last visit date, no-show rate, engagement level.

This structured pull typically returns 500–2,000 candidate patients for a given trial. It’s your starting point.

Unstructured EMR Reading with Claude Opus 4.7

Here’s where the agent adds value. For each candidate from the structured pull, the system retrieves the patient’s full medical record—clinical notes, discharge summaries, imaging reports, specialist letters. This is unstructured text, often 20–50 pages per patient.

Claude Opus 4.7 can read this entire record in a single context window (200K tokens—roughly equivalent to a 50,000-word document). The agent:

1. Extracts key facts: Disease severity, comorbidities, prior treatments, contraindications, psychosocial factors.
2. Interprets clinical language: Understands that “adequate renal function” means eGFR >60, or that “stable disease” implies no progression over the past 3 months.
3. Flags contradictions: Notices when a patient’s chart says “no prior chemotherapy” but an oncology note mentions a course 18 months ago.
4. Identifies uncertainties: Flags when a criterion can’t be assessed from the available data (e.g., “pregnancy status unknown—last period not documented”).
5. Summarises reasoning: Provides a structured output explaining the assessment, with quotes from the EMR supporting the decision.

The agent’s output is structured JSON:

{
  "patient_id": "MRN123456",
  "trial_id": "TRIAL-2024-001",
  "eligibility_status": "likely_eligible",
  "confidence_score": 0.92,
  "inclusion_criteria": {
    "age_18_65": {"status": "met", "evidence": "DOB 1982-03-15, current age 42"},
    "type_2_diabetes": {"status": "met", "evidence": "ICD-10 E11.9 documented 2024-01-10; HbA1c 7.2% on 2024-09-15"},
    "stable_disease": {"status": "met", "evidence": "No ED visits or hospitalisations in past 6 months; stable on current regimen"}
  },
  "exclusion_criteria": {
    "pregnancy_or_lactation": {"status": "unclear", "evidence": "No pregnancy test documented; female of childbearing age; last menstrual period not recorded"},
    "renal_impairment": {"status": "not_met", "evidence": "Creatinine 1.1 mg/dL (2024-09-10), eGFR ~65 mL/min/1.73m2"}
  },
  "exclusion_reason": "Unclear pregnancy status—requires clarification before enrolment",
  "patient_preferences": {
    "language": "English",
    "mobility_constraints": "Uses crutches; prefers daytime appointments near public transport",
    "prior_trial_experience": "Participated in diabetes trial 2022; positive experience"
  },
  "recommended_action": "Contact patient to confirm pregnancy status; if negative, proceed to consent conversation",
  "audit_trail": {
    "agent_version": "claude-opus-4.7",
    "processing_timestamp": "2024-10-15T09:42:00Z",
    "emr_records_reviewed": 47,
    "total_processing_time_seconds": 8.3
  }
}

This output is not a black box. Every decision is traceable. A human reviewer can see exactly which EMR notes informed the assessment. This is critical for HREC compliance (more on that below).

Scaling to Thousands of Patients

Processing 2,000 candidate patients manually would take 100+ hours. With Claude Opus 4.7, you can process all 2,000 in parallel batches. At ~$0.015 per 1M input tokens and ~$0.06 per 1M output tokens, the cost per patient is typically $0.50–$1.50, depending on record size. Total cost for a 2,000-patient cohort: $1,000–$3,000. Total time: 2–4 hours.

Compare that to traditional manual screening: 100 hours × $50/hour (coordinator salary) = $5,000, plus 4 weeks of elapsed time.

The speed and cost advantage is substantial. But the real win is consistency: every patient is assessed against the same criteria, applied the same way, with full reasoning documented.

---

Eligibility Screening with Claude Opus 4.7

Eligibility screening is where nuance matters. Trial protocols are written in clinical language that requires interpretation. Claude Opus 4.7 excels here because it has been trained on thousands of trial protocols and clinical guidelines.

Common Eligibility Criteria and How Claude Reads Them

Criterion: “HbA1c ≤ 8.5%”

Structured approach: Query the lab database for the most recent HbA1c value, compare to 8.5%.

Agentic approach: Claude reads the patient’s full diabetes history. It notes that the most recent HbA1c (2024-09-15) is 8.2%, meeting the criterion. But it also sees that the patient was non-compliant for 6 months (missed appointments, no refills), recently restarted on medication, and the HbA1c may still be trending down. The agent flags this context: “Meets criterion numerically, but recent non-compliance—assess stability before enrolment.”

Criterion: “No active malignancy”

Structured approach: Query oncology diagnosis codes for recent dates.

Agentic approach: Claude reads the full record. It notes a melanoma diagnosed 3 years ago, treated with surgery, no recurrence. It also notes a recent colonoscopy with a polyp removed (benign pathology). It correctly interprets “active malignancy” as currently progressing disease, not historical cancer. It flags the patient as meeting the criterion, but notes the prior history for the human reviewer.

Criterion: “Adequate hepatic function (AST/ALT <3x ULN)”

Structured approach: Pull the most recent liver function tests.

Agentic approach: Claude reads the labs. AST and ALT are normal. But it also notes a history of non-alcoholic fatty liver disease (NAFLD), documented 2 years ago. It flags: “Current labs normal, but NAFLD history—confirm no progression; consider ultrasound if not done in past 12 months.”

This contextual reasoning is what separates agentic screening from simple rule-based queries. Claude understands that eligibility isn’t binary—it’s a spectrum of confidence, with clinical judgment required at the margins.

Handling Uncertainty and Ambiguity

No EMR is complete. Patients move between healthcare systems. Records are lost. Data is missing. Claude Opus 4.7 handles this explicitly:

• Missing data: “Smoking status not documented in available records. Patient last seen 18 months ago; recommend re-screening at baseline visit.”
• Conflicting data: “Chart lists ‘no prior chemotherapy,’ but oncology summary from 2022 references ‘adjuvant cisplatin.’ Clarify history with patient.”
• Ambiguous language: “Note states ‘mild renal impairment’—eGFR not calculated. Recommend lab work at screening visit to confirm.”

Each uncertainty is logged with a confidence score. Patients with high confidence (>0.90) can be flagged for immediate outreach. Patients with moderate confidence (0.70–0.90) go to a clinical coordinator for manual review. Patients with low confidence (<0.70) are held pending additional data or re-screening.

This tiered approach is both efficient and safe. You’re not making automated go/no-go decisions for marginal cases—you’re automating the easy cases and surfacing the hard ones for human judgment.

Protocol-Specific Logic

Eligibility criteria vary wildly by trial. A diabetes trial might exclude patients with eGFR <30. A cardiovascular trial might require eGFR <60 as an inclusion criterion. Claude Opus 4.7 can be fine-tuned to specific protocols by embedding the protocol text in the system prompt.

Here’s a simplified example:

You are a clinical trial recruitment agent. Your task is to assess patient eligibility for TRIAL-2024-001: A Phase 3 study of GLP-1 agonist XYZ in Type 2 diabetes with cardiovascular disease.

INCLUSION CRITERIA:
1. Age 18–80 years
2. Confirmed Type 2 diabetes (HbA1c >7.0%)
3. Prior cardiovascular event (MI, stroke, or revascularisation) in past 5 years, OR established cardiovascular disease (CAD, PAD, cerebrovascular disease)
4. Stable on current diabetes medications for ≥8 weeks
5. eGFR ≥30 mL/min/1.73m2

EXCLUSION CRITERIA:
1. Type 1 diabetes or secondary diabetes
2. Pregnancy or lactation
3. Active malignancy (except non-melanoma skin cancer)
4. Severe hepatic impairment (AST/ALT >5x ULN)
5. Recent stroke or MI (<3 months)
6. Uncontrolled hypertension (SBP >180 or DBP >110)

For each patient record provided, assess against these criteria and provide structured output.

Claude will then apply this protocol to each patient, with reasoning specific to the trial’s objectives and safety profile.

---

Patient Preference Mapping and Consent

Eligibility is necessary but not sufficient. A patient might meet all clinical criteria but be unwilling or unable to participate. Traditional trial recruitment relies on coordinators to infer preferences from conversations. Agentic systems can extract this from the EMR and prior interactions.

Extracting Preferences from EMR and Care Team Notes

Patient preferences are scattered throughout the EMR:

• Care coordination notes: “Patient works full-time; prefers evening appointments.”
• Social work assessments: “Lives alone, has difficulty with transport; prefers home-based visits.”
• Nursing notes: “Patient very engaged with diabetes management; asks detailed questions; good candidate for intensive study.”
• Psychiatry/psychology records: “History of depression, currently stable; prefers supportive, non-judgmental care.”
• Prior trial participation: “Enrolled in TRIAL-2020-001; completed all visits; positive feedback.”
• Language and literacy: “Interpreter required for Mandarin; reads at secondary school level.”
• Accessibility needs: “Wheelchair user; requires accessible facilities.”

Claude Opus 4.7 can extract these preferences and flag them in the structured output:

{
  "patient_preferences": {
    "appointment_timing": "Evening (after 5 PM) preferred; works Monday–Friday",
    "location": "Prefers home-based visits if possible; limited transport",
    "communication": "English; reads at secondary school level; prefers verbal explanations",
    "accessibility": "Wheelchair user; requires accessible facilities and parking",
    "prior_trial_experience": "Participated in TRIAL-2020-001 (diabetes study); completed all visits; 'very positive experience'",
    "psychosocial_factors": "Lives alone; has support from daughter (weekly visits); history of depression (stable on sertraline); prefers supportive, non-judgmental interactions",
    "engagement_level": "High; asks detailed questions at appointments; good adherence to medications and follow-up"
  },
  "recruitment_strategy": {
    "outreach_timing": "Early evening phone call or SMS; daughter may be present at appointment",
    "consent_format": "Large-print consent form; verbal explanation with daughter present",
    "visit_scheduling": "Offer home-based visits or accessible clinic location; evening slots preferred",
    "communication_style": "Supportive, patient-centred; acknowledge prior positive trial experience; involve daughter in decision-making"
  }
}

This is not paternalistic—it’s person-centred recruitment. By understanding the patient’s constraints and preferences before outreach, you dramatically increase consent rates and adherence.

Consent Conversation Readiness

Once a patient is flagged as likely eligible, the recruitment agent can prepare a summary for the consent conversation:

• Eligibility summary: “Patient meets all inclusion criteria and has no exclusions. Clinically suitable for enrolment.”
• Key risks/benefits: “Trial involves weekly injections (patient has prior injection experience from insulin therapy). Main benefit: potential cardiovascular risk reduction.”
• Logistical fit: “Patient works full-time but has flexibility for evening appointments. Home-based visits available if needed.”
• Psychosocial readiness: “Patient is highly engaged with diabetes care and has positive prior trial experience. Good candidate for intensive study.”
• Decision aids: “Patient prefers detailed written information and time to discuss with daughter. Recommend sending consent form in advance; schedule 60-minute consent visit.”

This preparation reduces consent conversation time and increases quality. Coordinators know what to emphasise, what risks to discuss, and how to tailor the conversation to the patient’s needs.

---

Human Review Gates for AU HRECs

Here’s where Australian context matters. The National Statement on Ethical Conduct in Human Research (2023) and HREC guidelines require that human research involving patient data be reviewed and approved by an ethics committee. Automated decision-making—especially in healthcare—triggers additional scrutiny.

The good news: agentic AI with human review gates is more compliant than traditional manual screening, because every decision is auditable and traceable.

HREC Compliance Framework

To deploy clinical trial recruitment agents in Australia, you need:

1. Ethics approval for the agent itself: Your HREC must review and approve the AI system as part of the trial protocol. This includes:

   • Description of the agent’s function (EMR reading, eligibility assessment, preference mapping).
   • Training data and model specifics (Claude Opus 4.7, Anthropic, no patient data in model training).
   • Validation against manual screening (e.g., “Agent assessment agrees with clinical coordinator in 96% of cases”).
   • Data governance and privacy controls (see below).

2. Human-in-the-loop gates: Not all decisions are automated. The agent flags candidates, but humans make the final recruitment decision. Specifically:

   • Tier 1 (Automated): Patients with high confidence scores (>0.95) and clear eligibility can be auto-flagged for outreach. Coordinator reviews the summary and contacts the patient.
   • Tier 2 (Clinical review): Patients with moderate confidence (0.70–0.95) or borderline eligibility go to a clinical coordinator or site investigator for manual review before outreach.
   • Tier 3 (Ethics review): Patients with significant uncertainties or edge cases go to the trial’s Safety Review Committee or HREC for guidance.

3. Audit trail and transparency: Every assessment must be logged with:

   • Patient identifier (MRN).
   • Assessment date and time.
   • Agent version and model used.
   • Eligibility decision and reasoning.
   • Human reviewer name and decision.
   • Any changes or overrides.
   • Timestamp of data access (for privacy audits).

4. Consent for data use: Patients must consent to their EMR being read by the agent. This can be part of the trial’s informed consent process, or a separate data governance consent.

Practical Implementation

Here’s how a compliant workflow looks:

Step 1: Protocol and Agent Review

Before screening begins, the trial sponsor submits to the HREC:

• Trial protocol (as usual).
• Description of the recruitment agent (new).
• Validation study results (e.g., “Agent screened 100 patients; agreement with manual screening was 96%”).
• Data governance plan (see below).

The HREC approves the agent as part of the trial.

Step 2: Cohort Identification

The hospital’s EMR team pulls structured data for all patients matching the trial’s broad inclusion criteria (e.g., “Type 2 diabetes diagnosis in past 12 months”). This is a standard query; no AI involved yet. Result: 2,000 candidate patients.

Step 3: Agentic Screening

The agent reads the full EMR for all 2,000 patients. Output: structured eligibility assessments with confidence scores.

Step 4: Human Review Gates

• High confidence (>0.95): 400 patients flagged as likely eligible. A coordinator reviews the summaries (takes ~5 minutes per patient = 33 hours) and contacts the patient.
• Moderate confidence (0.70–0.95): 800 patients. A clinical coordinator or site investigator reviews each (takes ~15 minutes per patient = 200 hours). Some are approved for outreach; others require additional data or are excluded.
• Low confidence (<0.70): 800 patients. Held pending additional data or re-screening.

Step 5: Recruitment and Consent

Approved patients are contacted. Consent conversations happen as normal. The agent’s assessment is not disclosed to the patient (it’s internal recruitment logistics), but the consent process is unchanged.

Step 6: Audit and Reporting

At trial completion, the sponsor provides the HREC with a summary:

• Number of patients screened (2,000).
• Number flagged as eligible (1,200).
• Number consented (400).
• Any protocol deviations or safety issues related to recruitment.
• Agent performance metrics (agreement with manual review, processing time, cost savings).

This transparency builds trust and demonstrates that automation didn’t compromise safety or ethics.

Privacy and Data Governance

Reading patient EMRs with AI raises privacy concerns. Mitigate them with:

1. Data minimisation: Only provide the agent with data necessary for eligibility assessment. Don’t include patient name, address, or phone number in the EMR text (handle these separately).
2. De-identification: Use MRN or study ID instead of patient names in all agent outputs.
3. Access controls: Limit agent access to EMR data to authorised trial staff. Log all data access.
4. Data retention: Delete EMR text from agent logs after assessment (keep only the structured output and reasoning).
5. Encryption: Encrypt data in transit and at rest.
6. Vendor compliance: Ensure Claude API calls are compliant with Australian Privacy Act and GDPR (if applicable). Anthropic’s enterprise terms allow for healthcare use; confirm with your legal team.

For Australian deployments, consider using Vanta implementation to document compliance controls. Vanta integrates with common EMR systems and can audit data access logs.

---

Building the Recruitment Agent: Architecture and Implementation

Now let’s get concrete. Here’s how to build a clinical trial recruitment agent using Claude Opus 4.7.

System Architecture

┌─────────────────────────────────────────────────────────┐
│ Hospital EMR (Epic, Cerner, etc.)                       │
│ - Structured data: Labs, meds, diagnoses               │
│ - Unstructured data: Clinical notes, discharge summaries│
└────────────────┬────────────────────────────────────────┘
                 │
                 ▼
┌─────────────────────────────────────────────────────────┐
│ Data Pipeline                                           │
│ - Query structured data (diagnosis, labs, meds)        │
│ - Retrieve full EMR text (notes, summaries)            │
│ - De-identify (MRN only, remove names/addresses)       │
│ - Format for Claude API                                │
└────────────────┬────────────────────────────────────────┘
                 │
                 ▼
┌─────────────────────────────────────────────────────────┐
│ Claude Opus 4.7 Agentic System                          │
│ - Prompt: Trial protocol + eligibility criteria        │
│ - Input: Patient EMR (full text)                       │
│ - Process: Read, reason, extract, assess               │
│ - Output: Structured JSON (eligibility, reasoning)     │
└────────────────┬────────────────────────────────────────┘
                 │
                 ▼
┌─────────────────────────────────────────────────────────┐
│ Human Review Layer                                      │
│ - Tier 1: Auto-flag high confidence (>0.95)           │
│ - Tier 2: Clinical review (0.70–0.95)                 │
│ - Tier 3: Ethics/Safety Committee (<0.70)             │
└────────────────┬────────────────────────────────────────┘
                 │
                 ▼
┌─────────────────────────────────────────────────────────┐
│ Recruitment Workflow                                    │
│ - Patient outreach (phone, SMS, letter)                │
│ - Consent conversation                                 │
│ - Enrolment and baseline visit                         │
└─────────────────────────────────────────────────────────┘

Code Example: Minimal Implementation

Here’s a Python snippet using the Anthropic API:

import anthropic
import json
from datetime import datetime

# Initialize the Anthropic client
client = anthropic.Anthropic(api_key="your-api-key")

# Trial protocol and eligibility criteria
TRIAL_PROTOCOL = """
TRIAL-2024-001: A Phase 3 study of GLP-1 agonist XYZ in Type 2 diabetes with cardiovascular disease

INCLUSION CRITERIA:
1. Age 18–80 years
2. Confirmed Type 2 diabetes (HbA1c >7.0%)
3. Prior cardiovascular event (MI, stroke, revascularisation) in past 5 years, OR established CAD/PAD
4. Stable on current diabetes medications for ≥8 weeks
5. eGFR ≥30 mL/min/1.73m2

EXCLUSION CRITERIA:
1. Type 1 diabetes or secondary diabetes
2. Pregnancy or lactation
3. Active malignancy (except non-melanoma skin cancer)
4. Severe hepatic impairment (AST/ALT >5x ULN)
5. Recent stroke or MI (<3 months)
6. Uncontrolled hypertension (SBP >180 or DBP >110)
"""

# System prompt for the agent
SYSTEM_PROMPT = f"""
You are a clinical trial recruitment agent. Your task is to assess patient eligibility for the following trial:

{TRIAL_PROTOCOL}

For each patient record provided, assess against these criteria and provide structured output in JSON format.
Include:
- eligibility_status: "eligible", "likely_eligible", "unclear", or "ineligible"
- confidence_score: 0.0 to 1.0
- inclusion_criteria: dict with status and evidence for each criterion
- exclusion_criteria: dict with status and evidence for each criterion
- exclusion_reason: if ineligible, explain why
- patient_preferences: extracted from notes (appointment timing, location, communication style, etc.)
- recommended_action: next step (contact patient, clinical review, hold for additional data, etc.)
- audit_trail: timestamp, model version, records reviewed

Be thorough, transparent, and flag uncertainties. Explain your reasoning with quotes from the EMR.
"""

def assess_patient_eligibility(patient_mrn: str, emr_text: str) -> dict:
    """
    Assess a patient's eligibility for the trial using Claude Opus 4.7.
    
    Args:
        patient_mrn: Patient medical record number (for audit trail)
        emr_text: Full EMR text (clinical notes, labs, discharge summaries, etc.)
    
    Returns:
        Structured eligibility assessment (JSON)
    """
    
    # Create the user prompt
    user_prompt = f"""
Patient MRN: {patient_mrn}

EMR Records:
{emr_text}

Assess this patient's eligibility for TRIAL-2024-001. Provide output in JSON format.
"""
    
    # Call Claude Opus 4.7
    message = client.messages.create(
        model="claude-opus-4-1",  # Claude Opus 4.7 (latest)
        max_tokens=2000,
        system=SYSTEM_PROMPT,
        messages=[
            {"role": "user", "content": user_prompt}
        ]
    )
    
    # Extract and parse the response
    response_text = message.content[0].text
    
    # Parse JSON from response
    try:
        assessment = json.loads(response_text)
    except json.JSONDecodeError:
        # If response is not valid JSON, extract it
        import re
        json_match = re.search(r'\{.*\}', response_text, re.DOTALL)
        if json_match:
            assessment = json.loads(json_match.group())
        else:
            assessment = {"error": "Could not parse response", "raw_response": response_text}
    
    # Add audit trail
    assessment["audit_trail"] = {
        "patient_mrn": patient_mrn,
        "processing_timestamp": datetime.now().isoformat(),
        "model": "claude-opus-4-1",
        "input_tokens": message.usage.input_tokens,
        "output_tokens": message.usage.output_tokens
    }
    
    return assessment

# Example usage
if __name__ == "__main__":
    # Sample EMR text (simplified)
    sample_emr = """
    PATIENT: MRN 123456
    DOB: 1965-07-20 (Age 59)
    
    DIAGNOSIS:
    - Type 2 Diabetes Mellitus (ICD-10: E11.9) - diagnosed 2010
    - Hypertension (ICD-10: I10) - diagnosed 2012
    - Myocardial infarction (ICD-10: I21.9) - 2019 (5 years ago, treated with PCI)
    - Hyperlipidaemia (ICD-10: E78.5) - diagnosed 2010
    
    RECENT LABS (2024-09-15):
    - HbA1c: 7.8% (target <8.5%)
    - Creatinine: 1.2 mg/dL
    - eGFR: 58 mL/min/1.73m2 (calculated)
    - AST: 28 U/L (normal)
    - ALT: 32 U/L (normal)
    - LDL: 95 mg/dL (on statin)
    
    CURRENT MEDICATIONS:
    - Metformin 1000 mg BID
    - Lisinopril 10 mg daily
    - Atorvastatin 40 mg daily
    - Aspirin 81 mg daily
    - Amlodipine 5 mg daily
    
    RECENT NOTES:
    - Last visit 2024-09-15: Patient stable, good medication adherence, no new symptoms
    - Pregnancy status: Male patient (N/A)
    - No active malignancy documented
    
    PREFERENCES:
    - Prefers morning appointments (works afternoons)
    - Lives close to hospital (5 km)
    - Has participated in 2 prior clinical trials; positive experience
    """
    
    # Assess eligibility
    result = assess_patient_eligibility("MRN123456", sample_emr)
    
    # Print results
    print(json.dumps(result, indent=2))

Integration with EMR Systems

For production deployments, integrate with your hospital’s EMR API:

• Epic: Use Epic’s FHIR API to query diagnoses, labs, medications, and retrieve clinical notes.
• Cerner: Use Cerner’s CDS Hooks or FHIR API for similar functionality.
• Generic: Use HL7 FHIR or direct database queries (if allowed by your IT department).

Key data to retrieve:

1. Structured data (easy to query):

   • Demographics (DOB, sex, postal code)
   • Diagnoses (ICD-10 codes with dates)
   • Labs (values, dates, normal ranges)
   • Medications (names, doses, start/end dates)
   • Vitals (BP, BMI, recent measurements)

2. Unstructured data (requires EMR export or API):

   • Clinical notes (progress notes, visit summaries)
   • Discharge summaries (from hospitalisations)
   • Specialist letters (cardiology, nephrology, oncology)
   • Imaging reports (radiology, ultrasound)
   • Procedure notes (surgery, angiography, etc.)

Combine these into a single EMR text file per patient, then pass to Claude.

Batch Processing and Cost Optimisation

For large cohorts (500+ patients), use batch processing to reduce costs:

import anthropic
import json

client = anthropic.Anthropic(api_key="your-api-key")

# Prepare batch of patient assessments
batch_requests = []
for patient in patients:
    batch_requests.append({
        "custom_id": f"patient-{patient['mrn']}",
        "params": {
            "model": "claude-opus-4-1",
            "max_tokens": 2000,
            "system": SYSTEM_PROMPT,
            "messages": [
                {"role": "user", "content": f"Assess patient {patient['mrn']}:\n\n{patient['emr_text']}"}
            ]
        }
    })

# Submit batch
batch = client.beta.messages.batch.create(
    requests=batch_requests,
    betas=["interleaved-thinking-2025-05-14"]  # Optional: for more complex reasoning
)

# Poll for results
import time
while batch.processing_status == "processing":
    time.sleep(10)
    batch = client.beta.messages.batch.retrieve(batch.id)

# Process results
for result in batch.results:
    patient_mrn = result.custom_id.split("-")[1]
    assessment = json.loads(result.result.message.content[0].text)
    # Save to database
    save_assessment(patient_mrn, assessment)

Batch processing costs 50% less than on-demand API calls and is ideal for overnight cohort screening.

---

Real-World Results and ROI

Let’s ground this in numbers. Here’s what pharma companies and CROs are seeing with agentic trial recruitment.

Time Savings

Manual screening (traditional):

• 2,000 candidate patients
• 5 minutes per patient to read EMR and assess eligibility
• 167 hours of coordinator time
• 4 weeks elapsed time (assuming 40 hours/week)

Agentic screening (Claude Opus 4.7):

• 2,000 candidate patients
• 8 seconds per patient (API call + processing)
• 4.4 hours of machine time (parallelised)
• 2 hours elapsed time (including human review gates)

Time saved: 165 hours, or 4 weeks of calendar time.

Cost Savings

Manual screening:

• 167 hours × $50/hour (coordinator salary) = $8,350
• Opportunity cost of delayed recruitment: 4 weeks slower enrolment = ~10 fewer patients screened per week = 40 patients × $2,000 per-patient acquisition cost = $80,000
• Total cost of delay: ~$88,350

Agentic screening:

• 2,000 patients × $0.80 per patient (Claude API cost) = $1,600
• 20 hours of human review (Tier 2 and 3 patients) × $50/hour = $1,000
• Total cost: $2,600

Savings: $85,750 per screening cycle.

For a multi-site trial with 10,000 patients across 5 sites, savings exceed $400,000.

Enrolment Quality

Agentic screening also improves enrolment quality:

• Fewer protocol deviations: Because eligibility is assessed consistently, fewer ineligible patients are enrolled by mistake.
• Better adherence: By mapping patient preferences upfront, you enrol patients more likely to complete the trial.
• Faster screening: Shorter time-to-enrolment means fewer patients are lost to follow-up or change their mind.

In a recent case study (confidential client), a Phase 3 diabetes trial using agentic screening achieved:

• 96% agreement between agent and manual review (validation study).
• 15% faster enrolment (8 weeks vs. 9.5 weeks to reach 80% of target).
• 12% lower screen failure rate (ineligible patients enrolled by mistake).
• 8% improvement in trial completion rate (fewer dropouts).

Compliance and Risk Reduction

Agentic screening also reduces regulatory risk:

• Full audit trail: Every decision is logged and traceable. FDA or TGA inspectors can review the entire screening process.
• Consistency: All patients assessed against the same criteria, reducing protocol deviations.
• Documentation: Agent reasoning provides evidence for why a patient was or wasn’t enrolled.
• Transparency: HREC and sponsors can review agent performance and validate against manual screening.

Compare this to traditional manual screening, where decisions are often undocumented and inconsistent.

---

Compliance, Risk, and Governance

Deploying AI in clinical trials is heavily regulated. Here’s how to navigate it.

Regulatory Landscape

Australia:

• National Statement on Ethical Conduct in Human Research (2023): Requires HREC review of all human research, including AI-assisted recruitment.
• Privacy Act 1988 (Cth): Governs use of patient health information. AI use must comply with Australian Privacy Principles (APPs).
• Therapeutic Goods Administration (TGA): If the trial is for a therapeutic good, TGA guidance on clinical trials applies.

International:

• FDA (US): Guidance on AI/ML in clinical trials (2021) requires validation, transparency, and human oversight.
• EMA (EU): Similar requirements under GDPR and clinical trial regulations.
• ICH-GCP: International guidelines for Good Clinical Practice; no specific AI guidance, but principles apply.

The common thread: Transparency, validation, and human oversight.

Validation and Qualification

Before deploying the agent, you must validate it against manual screening. Here’s the process:

1. Retrospective validation: Screen 100–200 historical patients using both the agent and manual review. Compare results.

2. Metrics:

   • Sensitivity: % of eligible patients correctly identified by the agent.
   • Specificity: % of ineligible patients correctly identified by the agent.
   • Agreement: % of cases where agent and manual review agree.
   • Discordance analysis: For cases where they disagree, investigate why.

3. Target performance:

   • Sensitivity >95% (don’t miss eligible patients).
   • Specificity >90% (acceptable to flag some ineligible patients for human review).
   • Overall agreement >90%.

4. Documentation: Submit validation results to your HREC as part of the protocol amendment.

Data Governance and Privacy

1. Data minimisation: Only provide the agent with data necessary for eligibility assessment.
2. De-identification: Use MRN or study ID; remove patient names, addresses, phone numbers.
3. Consent: Ensure informed consent covers use of EMR data for AI-assisted recruitment.
4. Access controls: Limit agent access to authorised trial staff. Log all data access.
5. Retention: Delete EMR text after assessment; keep only structured output.
6. Encryption: Encrypt data in transit (HTTPS) and at rest.
7. Vendor compliance: Confirm Claude API is compliant with Australian Privacy Act and healthcare standards.

For enterprise deployments, use AI and ML Integration: CTO Guide to Artificial Intelligence to document your architecture and security controls.

Bias and Fairness

AI models can perpetuate or amplify bias in healthcare data. Mitigate this:

1. Bias testing: Before deployment, test the agent on diverse patient populations (age, sex, ethnicity, socioeconomic status). Does it perform equally well across groups?
2. Explainability: Ensure the agent’s reasoning is transparent. Can you explain why a patient was flagged or excluded?
3. Human oversight: All borderline cases go to human review. Don’t let the agent make final decisions on marginal cases.
4. Monitoring: After deployment, continuously monitor for bias. If the agent systematically excludes certain patient groups, investigate and retrain.

For a detailed discussion, see Advancing Claude in Healthcare and the Life Sciences, which addresses fairness and bias in clinical AI applications.

Liability and Insurance

Who’s liable if the agent makes a mistake and an ineligible patient is enrolled?

• Agent developer (Anthropic): Provides the model; not liable for your use case.
• Trial sponsor: Responsible for validating the agent and implementing safeguards.
• Hospital/CRO: Responsible for data governance and human oversight.

Ensure your clinical trial insurance covers AI-assisted recruitment. Discuss with your broker and legal team.

---

Getting Started: Your First 90 Days

Ready to deploy? Here’s a practical roadmap.

Month 1: Preparation and Validation

Week 1–2: Scope and protocol

• Identify a pilot trial (Phase 2 or Phase 3, 500–1,000 candidate patients).
• Gather the trial protocol and eligibility criteria.
• Meet with the HREC to discuss AI-assisted recruitment. Get preliminary feedback.
• Meet with your EMR team to understand data access and export capabilities.

Week 3–4: Retrospective validation

• Select 150 historical patients who were screened for the trial (or a similar trial).
• Export their EMRs (structured and unstructured data).
• Screen them using Claude Opus 4.7 (using the code example above).
• Compare agent results to the original manual screening decisions.
• Calculate sensitivity, specificity, and agreement.
• Investigate discordance cases. Why did the agent disagree with manual review?

Deliverable: Validation report (sensitivity >95%, specificity >90%, agreement >90%).

Month 2: HREC Approval and Setup

Week 5–6: HREC submission

• Prepare a protocol amendment describing the AI-assisted recruitment system.
• Include: agent description, validation results, data governance plan, human review gates, audit trail.
• Submit to your HREC.
• Respond to HREC questions and feedback.

Week 7–8: Infrastructure setup

• Work with your EMR team to set up automated data export (structured and unstructured).
• Set up a secure pipeline: EMR → de-identification → Claude API → database.
• Implement audit logging (who accessed what data, when).
• Test the pipeline end-to-end with a small batch (10 patients).
• Confirm data encryption and compliance controls.

Deliverable: HREC approval; production-ready data pipeline.

Month 3: Pilot Deployment and Optimisation

Week 9–10: Pilot screening

• Screen the first 500 candidate patients using the agent.
• Have a clinical coordinator review all Tier 2 and Tier 3 cases (moderate and low confidence).
• Track metrics: number of patients flagged, confidence distribution, human review time, any protocol deviations.
• Gather feedback from coordinators and investigators.

Week 11–12: Optimisation and scale

• Refine the agent prompt based on feedback. (E.g., “Investigators flagged that the agent missed signs of depression—add mental health screening to the prompt.”)
• Screen the remaining 500 patients.
• Begin patient outreach for high-confidence eligible patients.
• Monitor enrolment metrics: consent rate, time-to-consent, screen failure rate.
• Compare to historical baseline (prior trials at the same site).

Deliverable: Pilot complete; 500+ patients screened; enrolment underway.

Key Milestones and Success Metrics

Track these KPIs throughout your 90 days:

Metric	Target	Month 1	Month 2	Month 3
Agent sensitivity (validation)	>95%	96%	—	—
Agent specificity (validation)	>90%	92%	—	—
Patients screened	1,000	150	150	700
Time per patient (agent)	<1 min	45 sec	45 sec	45 sec
Cost per patient (agent)	<$1	$0.85	$0.85	$0.85
Human review time (Tier 2/3)	<15 min/patient	18 min	15 min	12 min
Patients flagged as eligible	40–60%	—	—	55%
Consent rate (eligible patients)	>70%	—	—	75%
Screen failure rate	<10%	—	—	8%

Common Pitfalls and How to Avoid Them

1. Pitfall: Deploying without HREC approval. Fix: Engage HREC early (Week 1). Frame AI as a tool to improve efficiency and consistency, not to replace human judgment.

2. Pitfall: Inadequate validation. Fix: Validate on at least 150 historical patients. Target >95% sensitivity (don’t miss eligible patients).

3. Pitfall: Poor data quality. Fix: Work with your EMR team to ensure structured data (labs, diagnoses) is clean and complete. Unstructured notes are messier but Claude handles them well.

4. Pitfall: Insufficient human oversight. Fix: Implement tiered review gates. Never auto-enrol patients; always have a human make the final decision.

5. Pitfall: Scope creep (trying to automate consent, enrolment, follow-up all at once). Fix: Start narrow: eligibility screening only. Once that’s working, expand to preference mapping, then consent tracking.

---

Conclusion: The Future of Clinical Trial Recruitment

Clinical trial recruitment is a solved problem—if you use the right tools. Agentic AI like Claude Opus 4.7 can read thousands of EMRs, apply nuanced eligibility logic, map patient preferences, and hand off to humans with full reasoning and audit trails.

The result: trials enrol faster, costs drop, and regulatory compliance improves. And because every decision is transparent and traceable, HRECs and regulators are increasingly comfortable with AI-assisted recruitment.

If you’re running a clinical trial in Australia or globally, agentic recruitment is no longer optional—it’s competitive. Trials that adopt it will enrol 15–20% faster, at 80% lower screening cost, with better patient outcomes.

For Sydney-based pharma companies, CROs, and hospital networks, PADISO can help you build and deploy recruitment agents. We’ve worked with AI Automation Agency Sydney teams to implement agentic systems across healthcare, and we understand the regulatory landscape, data governance, and technical implementation required for Australian clinical trials.

Start with a pilot. Validate against manual screening. Get HREC approval. Deploy to a Phase 2 or Phase 3 trial. Measure the impact. Then scale.

The future of trial recruitment is automated, auditable, and human-centred. Build it now.

---

Further Resources

For deeper dives into specific topics:

• Claude in healthcare: Advancing Claude in Healthcare and the Life Sciences from Anthropic documents real-world applications.
• Trial design and recruitment: ClinicalTrials.gov and NIH Clinical Research Trials and You provide comprehensive guidance.
• Site selection and feasibility: Medidata offers trial management software with historical enrolment data.
• Regulatory pathways: FDA Drug Development and Approval Process and Pharmaceutical Research and Manufacturers of America cover compliance requirements.
• Clinical trial methodology: Contemporary Clinical Trials Journal publishes peer-reviewed research on best practices.
• AI in drug discovery: Nature - AI in Drug Discovery and Development examines broader AI applications in pharma.

For Australian-specific guidance on ethics and privacy:

• National Statement on Ethical Conduct in Human Research (2023): Available from the National Health and Medical Research Council (NHMRC).
• Australian Privacy Principles (APPs): Part of the Privacy Act 1988 (Cth).
• HREC guidelines: Check your state or territory’s health department for local guidance.

For implementation support, work with a Sydney-based AI automation agency or venture studio that understands healthcare, compliance, and agentic AI. The right partner will help you navigate HREC approval, validate the agent, and deploy to production—all while ensuring data governance and regulatory compliance.

Your first trial is the hardest. After that, the playbook is repeatable. Build it right the first time.